RXST vs. SLNO
RXST (RxSight, Inc.) and SLNO (Soleno Therapeutics, Inc.) are both stocks. Both are in the Healthcare sector — RXST in Medical Devices, SLNO in Biotechnology. Over the past 3 years, RXST returned -43.12%/yr vs 122.08%/yr for SLNO. At a 0.18 correlation, their price movements are largely independent.
Performance
RXST vs. SLNO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, RXST achieves a -54.03% return, which is significantly lower than SLNO's 14.49% return.
RXST
- 1D
- -3.04%
- 1M
- -35.09%
- YTD
- -54.03%
- 6M
- -59.61%
- 1Y
- -69.70%
- 3Y*
- -43.12%
- 5Y*
- —
- 10Y*
- —
SLNO
- 1D
- 0.00%
- 1M
- 0.21%
- YTD
- 14.49%
- 6M
- 4.51%
- 1Y
- -31.50%
- 3Y*
- 122.08%
- 5Y*
- 28.47%
- 10Y*
- -5.77%
RXST vs. SLNO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
RXST RxSight, Inc. | -54.03% | -69.69% | -14.73% | 218.23% | 12.62% | -29.69% |
SLNO Soleno Therapeutics, Inc. | 14.49% | 3.00% | 11.68% | 1,932.83% | -67.80% | -54.95% |
Correlation
The correlation between RXST and SLNO is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.11 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.24 |
Correlation (All Time) Calculated using the full available price history since Aug 2, 2021 | 0.18 |
The correlation between RXST and SLNO shifts across timeframes, from 0.11 (1 year) to 0.24 (3 years), reflecting how their relationship changes across market environments.
Fundamentals
RXST:
$197.86M
SLNO:
$2.81B
RXST:
-$1.14
SLNO:
$1.81
RXST:
1.54
SLNO:
9.90
RXST:
0.74
SLNO:
5.67
RXST:
$127.48M
SLNO:
$285.01M
RXST:
$98.18M
SLNO:
$187.70M
RXST:
-$50.09M
SLNO:
$101.57M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RXST vs. SLNO — Risk / Return Rank
RXST
SLNO
RXST vs. SLNO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for RxSight, Inc. (RXST) and Soleno Therapeutics, Inc. (SLNO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| RXST | SLNO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.51 | ||
| Sortino ratioReturn per unit of downside risk | -1.29 | ||
| Omega ratioGain probability vs. loss probability | 0.80 | 0.96 | -0.17 |
| Calmar ratioReturn relative to maximum drawdown | -1.01 | -0.45 | -0.55 |
| Martin ratioReturn relative to average drawdown | -1.54 | -0.78 | -0.77 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| RXST | SLNO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.95 | -0.43 | -0.51 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.12 | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | -0.03 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.32 | -0.07 | -0.25 |
Drawdowns
RXST vs. SLNO - Drawdown Comparison
The maximum RXST drawdown since its inception was -92.55%, smaller than the maximum SLNO drawdown of -99.86%. Use the drawdown chart below to compare losses from any high point for RXST and SLNO.
Loading charts...
Drawdown Indicators
| RXST | SLNO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.55% | -99.86% | +7.31% |
Max Drawdown (1Y)Largest decline over 1 year | -69.47% | -66.04% | -3.43% |
Max Drawdown (3Y)Largest decline over 3 years | -92.55% | -66.04% | -26.51% |
Max Drawdown (5Y)Largest decline over 5 years | — | -94.96% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -99.06% | — |
Current DrawdownCurrent decline from peak | -92.55% | -91.92% | -0.63% |
Average DrawdownAverage peak-to-trough decline | -36.61% | -90.59% | +53.98% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 45.50% | 38.58% | +6.92% |
Volatility
RXST vs. SLNO - Volatility Comparison
RxSight, Inc. (RXST) has a higher volatility of 20.71% compared to Soleno Therapeutics, Inc. (SLNO) at 0.32%. This indicates that RXST's price experiences larger fluctuations and is considered to be riskier than SLNO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RXST | SLNO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 20.71% | 0.32% | +20.39% |
Volatility (6M)Calculated over the trailing 6-month period | 44.13% | 44.82% | -0.69% |
Volatility (1Y)Calculated over the trailing 1-year period | 73.69% | 69.01% | +4.68% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 69.12% | 243.64% | -174.52% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 69.12% | 185.28% | -116.16% |
Dividends
RXST vs. SLNO - Dividend Comparison
Neither RXST nor SLNO has paid dividends to shareholders.
Financials
RXST vs. SLNO - Financials Comparison
This section allows you to compare key financial metrics between RxSight, Inc. and Soleno Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
RXST vs. SLNO - Profitability Comparison
RXST - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, RxSight, Inc. reported a gross profit of 23.50M and revenue of 30.89M. Therefore, the gross margin over that period was 76.1%.
SLNO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Soleno Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 94.60M. Therefore, the gross margin over that period was 0.0%.
RXST - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, RxSight, Inc. reported an operating income of -17.83M and revenue of 30.89M, resulting in an operating margin of -57.7%.
SLNO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Soleno Therapeutics, Inc. reported an operating income of 31.28M and revenue of 94.60M, resulting in an operating margin of 33.1%.
RXST - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, RxSight, Inc. reported a net income of -15.88M and revenue of 30.89M, resulting in a net margin of -51.4%.
SLNO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Soleno Therapeutics, Inc. reported a net income of 31.38M and revenue of 94.60M, resulting in a net margin of 33.2%.
Frequently Asked Questions
RXST and SLNO have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
RXST has higher volatility (20.71%) compared to SLNO (0.32%). In terms of maximum drawdown, RXST dropped -92.55% vs SLNO's -99.86%.
SLNO currently has the higher Sharpe Ratio (-0.43 vs -0.95), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for RXST and SLNO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer